“Low-Risk” Prediction Rule for Pediatric Oncology Patients Presenting With Fever and Neutropenia
- 1 March 2000
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (5), 1012
- https://doi.org/10.1200/jco.2000.18.5.1012
Abstract
PURPOSE: To prospectively derive and validate a clinical prediction rule to allow a more tailored approach to the management of pediatric oncology outpatients presenting with fever and neutropenia. PATIENTS AND METHODS: The clinical prediction rule was derived over a 1-year period and then validated over the following 8 months in a new set of fever and neutropenia episodes. Patients were excluded if they presented with comorbidity or an abnormal chest x-ray (CXR). RESULTS: Significant bacterial infection (SBI; defined as any blood or urine culture positive for bacteria, interstitial or lobar consolidation on CXR, or unexpected death from infection) was documented in 43 of the 227 episodes. Multivariate analysis found four significant factors: bone marrow disease, general appearance unwell on initial examination, monocyte count less than 0.1 × 109/L, and peak oral or oral equivalent temperature greater than 39°C. Only the monocyte count contributed to determining a low-risk group, excluding SBI with 84% sensitivity (95% confidence interval [CI], 61% to 100%), 42% specificity (95% CI, 38% to 46%), and a negative predictive value of 92% (95% CI, 76% to 100%). If the monocyte count was ≥ 0.1 × 109/L at the time of presentation (low risk), the incidences of SBI and bacteremia were 8% and 5%, respectively, versus 25% and 17% in the high-risk group. When validated in a new population of 136 episodes of fever and neutropenia, the incidences of SBI and bacteremia in the low-risk group were 12% and 5%, respectively, and 25% and 19% in the high-risk group. CONCLUSION: Pediatric oncology outpatients with fever and neutropenia who present with an initial monocyte count of ≥ 0.1 × 109/L and do not have comorbidity or an abnormal CXR at the time of presentation are at lower risk for SBI and can be considered for less aggressive initial therapy.Keywords
This publication has 23 references indexed in Scilit:
- A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studiesBritish Journal of Haematology, 1997
- Low‐risk febrile neutropenia in a medical oncology unitAustralian and New Zealand Journal of Medicine, 1997
- A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremiaThe Journal of Pediatrics, 1996
- ORAL ANTIBIOTIC THERAPY FOR “LOW RISK” FEBRILE NEUTROPENIC EPISODES (FNE). † 912Pediatric Research, 1996
- Predicting the risk of bacteremia in childen with fever and neutropenia.Journal of Clinical Oncology, 1996
- The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsisCancer, 1996
- The challenge of vancomycin-resistant enterococci: A clinical and epidemiologic studyAmerican Journal of Infection Control, 1995
- Nosocomial Enterococci Resistant to Vancomycin—United States, 1989-1993Published by American Medical Association (AMA) ,1993
- Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patientsThe Lancet, 1992
- Duration of empiric antibiotic therapy in granulocytopenic patients with cancerAmerican Journal Of Medicine, 1979